Value of intraoperative post-conisation human papillomavirus testing in predicting residual or recurrence after treatment with a loop electrosurgical excision procedure in women with HR-HPV positive and cervical high-grade squamous intraepithelial lesion Authors: Weiting Xia, Xinyue Dai, Yan Hu, Simeng Yang, Chen Chen, Xiaolin Li Published: 2024 ABSTRACT AbstractObjectiveTo evaluate the feasibility of intraoperative human papillomavirus (IOP-HPV) testing for the prediction of postoperative treatment failure in patients with high-grade squamous intraepithelial lesion (HSIL) undergoing loop electrosurgical excisional procedure (LEEP).MethodsA total of 114 women diagnosed with HSIL by biopsy and/or endocervical curettage who underwent LEEP were included in a prospective cohort study. IOP-HPV testing was performed immediately after the procedure. Patients were followed up for 24 months. Logistic regression was used to analyse the factors influencing the residual or recurrent lesions. Further stratified analyses were performed to investigate the differences in prognosis of IOP-HPV positivity in patients of different age and menopausal status.Results1. Of the 114 patients, 6 (5.26%) were pathologically upgraded to cervical cancer, and 21 (18.42%) were lost to follow-up. Recurrence or residual HSIL lesions occurred in 9.20% (8/87) of cases. Of the 8 women who developed post-treatment HSIL, 7 (26.92%) were positive for IOP-HPV, and only 1 (1.64%) was negative for IOP-HPV (< 0.01).2. Transformation zones of type 2 (P = 0.0306) or type 3 (P = 0.0446), diagnosed as LSIL/negative by cervical biopsy (P = 0.0396), margin involvement (P = 0.0233), positive endocervical curettage after conisation (P = 0.0028), intraoperative HPV-positive (P < 0.01), cytological abnormalities (P = 0.0038), DNA ploidy positivity (P = 0.0172), postoperative HPV (P < 0.01) and DNA ploidy (P = 0.0078) positivity at 6 months were associated with higher risk of residual or recurrent lesions. 3. The results of the multivariate regression analysis showed that IOP-HPV positivity was the independent risk factor for residual or recurrent lesions (OR=10.69 , 95% CI:3.41, 33.51, P<0.01). IOP-HPV positivity was strongly associated with the occurrence of residual/recurrent LSIL (OR=6.42 , 95% CI:1.74, 23.70, P=0.0053) and HSIL (OR=32.08 , 95% CI:3.60, 285.64, P=0.0019).4. Stratified analyses showed that IOP-HPV positive in patients younger than 50 years or premenopausal patients was associated with a significantly higher risk of recurrence or residual lesions (p<0.05).ConclusionsIOP-HPV positivity is an independent risk factor for residual or recurrent HSIL lesions. In addition, IOP-HPV positivity was more associated with residual or recurrent lesions in those younger than 50 years or premenopausal. IOP-HPV testing may be of critical clinical value in providing the early and accurate prediction of residual or recurrent lesions.Keywords: HSIL, LEEP, IOP-HPV, Recurrence, Residual Introduction High-grade squamous intraepithelial lesion (HSIL) of the cervix is caused by persistent high-risk human papillomavirus (HPV) infection [1], and is a precursor of cervical cancer. Surgical excision by either cold knife conization, laser conization or loop electrosurgical excision procedure (LEEP) is the gold standard treatment [2]. However, approximately 15% of patients experience varying degrees of residual or recurrence after surgery [3]. A few studies have evaluated the risk of recurrence after LEEP in women with HSIL, but the results have been inconsistent [4–8]. Age, smoking, lesion size and severity, high-risk human papillomavirus (HR-HPV) type, and persistence of HR-HPV after treatment have each been shown to predict residual or recurrent CIN [9, 10]. In addition, margin involvement is a well-established risk factor for treatment failure [11–15]. There is still uncertainty and debate as to which risk factor or combination of factors most accurately predicts recurrence. It is known that most precancerous lesions are located in the transformation zone, and that after excision of the transformation zone, a high percentage of women will have clearance not only of the lesion but also of the HPV infection. Therefore, in women undergoing LEEP where the lesion is completely removed, we would expect the HPV test performed intraoperatively immediately after excision (the IOP HPV test) to be negative, and positive if the excision was incomplete. Therefore, this article attempts to evaluate the feasibility and utility of intraoperative HPV testing (IOP-HPV) performed in the residual cervix immediately after conisation for HSIL, and to determine whether it could be an early marker of disease clearance or persistence. We also analysed the population by age and menopausal status to see if there was a difference in the risk of recurrence. Materials and methods Data collection This prospective study included 114 patients with HSIL/CIN2-3 who underwent LEEP at the First Affiliated Hospital of Wenzhou Medical University between February 2021 and May 2022. The enrolled patients were all high-risk HPV (HR-HPV) positive and were diagnosed by colposcopically-directed biopsy (CDB) or endocervical curettage (ECC) within 90 days prior to treatment. All women were followed for a minimum of 24 months. Exclusion criteria were the presence of an immunosuppressive disorder and chronic treatment with immunosuppressive drugs, pathology upgraded to cervical cancer after LEEP, or for whom follow-up information was unavailable. The study was approved by the Institutional Review Board of the First Affiliated Hospital of Wenzhou Medical University (number: KY2020-053). Written informed consent was obtained from all participants. Before LEEP, the abnormal area was delineated with acetic acid and Lugol's solution and removed adjacent to the transformation zone, followed by selective coagulation of the surgical bed with a diathermic coagulation ball. Immediately after LEEP, cervical specimens were collected for IOP-HPV testing, cytology and DNA ploidy analysis of cervical exfoliated cells. ECC was performed at the end of the procedure. HPV genotyping was performed on specimens by PCR and flow fluorescence hybridisation. Cytology samples were interpreted by an experienced pathologist according to the Bethesda system [16]. For DNA ploidy analysis, after Feulgen staining of cervical cells, the samples were scanned by an automated high-resolution cellular DNA image analysis system. The system analysed multiple parameters of each sample nucleus and automatically performed cell counting and classification according to various characteristic parameters. Follow-up visits were scheduled at 6, 12 and 24 months. At each visit, liquid-based cytology (LBC), HPV testing and DNA ploidy analysis of cervical exfoliated cells were performed. Individuals with any of the three abnormalities underwent colposcopic cervical biopsy, and if the conversion zone was not completely visible or no abnormalities were found on colposcopy, ECC was performed. If all were negative, routine colposcopy and cervical biopsy were performed at 6 and 24 months after surgery. Lesions found within 6 months were considered residual, while those found after 6 months were considered recurrent. If HSIL or more severe lesions were found, a second surgical treatment was performed and follow-up was terminated. Statistical methods In this study, the included participants were categorized as “IOP-HPV positive” and “IOP-HPV negative”, continuous variables were described as “mean ± SD (standard deviation)”, categorical variables were described as “N (%)”, and comparisons of differences between the two groups were made using either the Kruskal-Wallis H test or the Chi-square test. We used logistic regression model to assess the association between IOP-HPV and postoperative residual/recurrence. In the analysis we developed three models, model I was unadjusted, model II was adjusted for type of transformation zone, IOP cytology, post-conisation endocervical curettage and model III was adjusted for type of transformation zone, pathology of colposcopy-guided biopsy, IOP cytology, IOP DNA ploidy analysis, cone margin, post-conisation endocervical curettage. Covariates were included as potential confounders in the adjusted models if they changed the estimates of IOP-HPV on postoperative residual/recurrence by more than 10% or were significantly associated with postoperative residual/recurrence. In addition, we performed interaction and stratified analysis by age and menopause in the sensitivity analyses. R language 4.2.1 was used to analyse all data. In all analyses, p < 0.05 was considered statistically significant. Results Patient characteristics Over the specified time period, 114 patients met the selection criteria and were included in the study. Histological examination of LEEP specimens revealed early cervical cancer (stage IA1/IA2) in six cases (5.26%), with 21 patients (18.42%) lost to follow-up (Fig. 1). The median age of all patients was 43 years, ranging from 25 to 62 years, 21.84% (19/87) were menopausal, and the median follow-up was 25 months (range 6–33 months). At baseline, all patients were positive for HR-HPV prior to treatment. Recurrence/residual HSIL lesions occurred in 9.20% (8/87) of cases and all of these patients received follow-up treatment. The median time to diagnosis of HSIL after LEEP was 10 months (range 6–14 months). Of the 8 women who developed HSIL after treatment, seven (26.92%) were positive for IOP-HPV and only one (1.64%) was negative for IOP-HPV (< 0.001). The characteristics of all patients are summarised in Table 1. Flow chart of the study Table 1Patient characteristicsCharacteristicIOP HPV (-)IOP HPV (+)P-valueAge, years Mean ± SD42.08 ± 9.2245.50 ± 10.880.180Age, years0.555 Age<4537(60.66%)14(53.85%) Age ≥ 4524(39.34%)12(46.15%)Age, years0.254 Age<5045(73.77%)16 (61.54%) Age ≥ 5016(26.23%)10 (38.46%)Menopause0.014 Premenopausal52(85.25%)16 (61.54%) Postmenopausal9 (14.75%)10 (38.46%)Transformation zone (%)0.010 Type 129(47.54%)4 (15.38%) Type 216(26.23%) 8 (30.77%) Type 316(26.23%)14 (53.85%)Preoperative HR-HPV test (%)0.726 Type 16 or 18 positive33(54.10%) 13 (50.00%) Other HR-HPV positive28(45.90%)13 (50.00%)Preoperative cytology (%)0.751 Negative 19(31.15%) 9 (34.62%) ASCUS/LSIL/HSIL42(68.85%)17 (65.38%)Pathology of colposcopy-guided biopsy (%)0.023 Negative/LSIL2(3.28%)5(19.23%) HSIL59(96.72%)21 (80.77%)Preoperative ECC0.019 Negative/LSIL24(39.34%)6 (23.08%) HSIL18(29.51%) 16 (61.54%) Not satisfactory19(31.15%)4 (15.38%)IOP/6-months testsIOP cytology0.001 Negative54(88.52%) 15 (57.69%) ≥ASC-US7(11.48%)11 (42.31%)IOP DNA ploidy analysis0.008 Negative44(72.13%) 11(42.31%) Positive17 (27.87%)15 (57.69%)Cone margin< 0.001 Negative58(95.08%) 17(65.38%) Positive3 (4.92%)9 (34.62%)Post-conisation ECC0.003 Negative60(98.36%) 20(76.92%) Positive1 (1.64%)6 (23.08%)Six-month cytology< 0.001 Negative53(86.89%) 13(50.00%) Positive0(0.00%) 3(11.54%) Unavailable8 (13.11%)10 (38.46%)Six-month DNA ploidy analysis0.006 Negative47(77.05%) 11 (42.31%) Positive6(9.84%) 5 (19.23%) Unavailable8 (13.11%)10 (38.46%)Six-month HPV< 0.001 Negative46(75.41%) 7 (26.92%) Positive 7(11.48%) 9 (34.62%) Unavailable8 (13.11%)10 (38.46%)Recurrence< 0.001 No55 (90.16%)12(46.15%) Yes6(9.84%) 14(53.85%) LSIL5(8.20%) 7(26.92%) HSIL1 (1.64%)7 (26.92%) Patient characteristics Factors associated with residual/recurrence Univariate regression analysis showed the ORs associated with residual/recurrence (Table 2). Patients with cervical transformation zones of type 2 (OR = 5.00; 95% CI = 1.16–21.51; P = 0.0306) and type 3 (OR = 4.29; 95% CI = 1.04–17.74; P = 0.0446) had a higher risk of residual or recurrent lesions than those with transformation zones of type 1. Interestingly, patients whose colposcopy-guided biopsy pathology was LSIL or negative (i.e., tissue from the cervical curettage was diagnosed as HSIL) had a significantly increased risk of postoperative recurrence compared to those whose colposcopy-guided biopsy pathology was HSIL (OR = 0.19; 95% CI = 0.04–0.92; P = 0.0396). Table 2Factors associated with residual/recurrenceOR (95% CI)P-valueAge, years1.01 (0.96, 1.06)0.7356Age, years Age<451.00.8865 Age ≥ 450.93 (0.34, 2.57)Age, years Age<501.00.9898 Age ≥ 501.01(0.34, 3.00)Menopause Premenopausal1.00.3180 Postmenopausal1.78 (0.57, 5.52)Transformation zone Type 11.0 Type 25.00 (1.16, 21.51)0.0306vType 34.29 (1.04, 17.74)0.0446Preoperative HR-HPV test Type 16 or 18 positive0.69 (0.25, 1.89)0.4681 Other HR HPV positive1.0Preoperative cytology Negative1.00.7588 ASCUS/LSIL/HSIL0.85 (0.30, 2.43)Pathology of colposcopy-guided biopsy Negative/LSIL1.00.0396 HSIL0.19 (0.04, 0.92)Preoperative ECC Negative/LSIL1.0 HSIL1.57 (0.52, 4.77)0.4248 Not satisfactory0.31 (0.06, 1.68)0.1751IOP/6-months testsIOP-HPV Negative1.0< 0.0001 Positive10.69 (3.41, 33.51)IOP cytology Negative1.00.0038 ≥ASCUS5.27 (1.71, 16.27)IOP DNA ploidy analysis Negative1.00.0172 Positive3.52 (1.25, 9.94)Cone margin Negative1.00.0233 Positive4.36 (1.22, 15.55)Post-conisation ECC Negative1.00.0028 Positive28.29 (3.15, 253.80)Six-month cytology Negative1.0 Positive8.15 (0.69, 96.97)0.0967 Unavailable1.57 (0.47, 5.19)0.4612Six-month DNA ploidy analysis Negative1.0 Positive6.53 (1.64, 26.06)0.0078 Unavailable2.09 (0.60, 7.33)0.2475Six-month HPV Negative1.0 Positive50.00 (9.85, 253.70)< 0.0001 Unavailable6.41 (1.35, 30.38)0.0193 Factors associated with residual/recurrence For pathological findings in LEEP specimens, margin involvement was significantly associated with residual/recurrence (P = 0.0233), with ORs of 4.36 (95% CI = 1.22, 15.55). Similarly, a positive result suggested by endocervical curettage after conisation significantly increased the risk of postoperative recurrence (OR = 28.29; 95% CI = 3.15–253.80; P = 0.0028). Patients with intraoperative HPV positivity (OR = 10.69; 95% CI = 3.41–33.51; P < 0.01), cytological abnormalities (OR = 5.27; 95% CI = 1.71–16.27; P = 0.0038) and DNA ploidy positivity (OR = 3.52; 95% CI = 1.25–9.94; P = 0.0172) all had a significantly increased risk of postoperative residual/recurrence. Meanwhile, patients with HPV positivity (OR = 50; 95% CI = 9.85–253.70; P < 0.01) or DNA ploidy positivity (OR = 6.53; 95% CI = 1.64–26.06; P = 0.0078) at 6 months post-operatively also had a significantly increased risk of recurrence, but unexpectedly, the increased risk in patients with abnormal cytology at 6 months post-operatively was not statistically significant. Multifactorial regression analysis of the association between intraoperative HPV positivity and postoperative residual/recurrence Table 3 shows the ORs and 95% CIs of the association between intraoperative HPV infection and postoperative residual or recurrent disease in the three regression models. In model I, we found that IOP-HPV positivity was a risk factor for residual or recurrent disease within 2 years of LEEP in women with HSIL (OR = 10.69, 95% CI:3.41, 33.51, P < 0.01). Based on these results, further analyses showed that IOP-HPV positive was strongly associated with the occurrence of residual/recurrent LSIL (OR = 6.42, 95% CI:1.74, 23.70, P = 0.0053) and HSIL (OR = 32.08, 95% CI:3.60, 285.64, P = 0.0019). More interestingly, the OR was significantly higher in the HSIL group than in the LSIL group (32.08 vs. 6.42). In models II and III, the above conclusions remained after adjustment for multiple confounders. IOP-HPV positive showed a robust positive correlation with residual/recurrent cervical lesions. Table 3Multifactorial analysis of the association between intraoperative HPV positivity and postoperative residual/recurrenceOutcomeModel IOR(95%CI) P-valueModel IIOR(95%CI) P-valueModel IIIOR(95%CI) P-valueNon- recurrence1.01.01.0recurrence10.69 (3.41, 33.51) < 0.00016.75 (1.85, 24.59) 0.00387.47 (1.94, 28.72) 0.0034LSIL6.42(1.74, 23.70) 0.00534.83 (1.17, 19.95) 0.02955.22 (1.20, 22.73) 0.0275HSIL32.08 (3.60, 285.64) 0.001916.83 (1.20, 236.37) 0.036237.52 (1.35, 1045.14) 0.0327Model I adjust for: NoneModel II adjust for: Type of transformation zone, IOP cytology, Post-conisation endocervical curettageModel III adjust for: Type of transformation zone, Pathology of colposcopy-guided biopsy, IOP cytology, IOP DNA ploidy analysis, Cone margin, Post-conisation endocervical curettage Multifactorial analysis of the association between intraoperative HPV positivity and postoperative residual/recurrence Model I adjust for: None Model II adjust for: Type of transformation zone, IOP cytology, Post-conisation endocervical curettage Model III adjust for: Type of transformation zone, Pathology of colposcopy-guided biopsy, IOP cytology, IOP DNA ploidy analysis, Cone margin, Post-conisation endocervical curettage Stratified associations between IOP-HPV and postoperative residual/recurrent lesion by age and menopause We performed further stratified analyses according to the age of the patients and whether they were menopausal or not (Fig. 2). The results showed that there was no significant difference in the risk of postoperative lesion residue/recurrence in patients with IOP-HPV positivity, whether they were over or under 45 years of age. In contrast, the risk of postoperative residual/recurrence was significantly higher in patients younger than 50 years than in those older than 50 years. According to models II and III, for patients with IOP-HPV positivity, the risk of postoperative recurrence was 29 times (Interaction-P = 0.0096) and 55.9 times (Interaction-P = 0.0120) higher for patients younger than 50 years, respectively. In addition, in accordance with Model II, the risk of postoperative lesion recurrence or residual disease in premenopausal women with IOP-HPV positivity is approximately 59 times higher than in postmenopausal women (Interaction-P = 0.0023). Furthermore, after adjusting for all confounders in model III, the ratio is 130 times higher (Interaction-P = 0.0027), which is still statistically significant. Stratified associations between IOP-HPV positivity and postoperative residual/recurrence according to baseline characteristics. a was adjusted for type of transformation zone, IOP cytology, post-conisation endocervical curettage. b was adjusted for type of transformation zone, pathology of colposcopy-guided biopsy, IOP cytology, IOP DNA ploidy analysis, cone margin, post-conisation endocervical curettage Discussion This is one of the few studies to evaluate IOP-HPV testing as an early marker for residual/recurrent cervical high-grade squamous intraepithelial lesion. The present study highlights positive IOP-HPV testing as an important risk factor for recurrence. More interestingly, for these HSIL patients with preoperative HR-HPV positivity, we found that if IOP-HPV testing was positive, being younger than 50 years or premenopausal was associated with a greater risk of residual or recurrent lesions after LEEP (P<0.05). It has been reported that approximately 15% of women treated for high-grade cervical intraepithelial neoplasia (CIN grade 2 or 3) develop residual or recurrent CIN grade 2 or 3 or cervical cancer [3, 17–20], with the majority of these diagnosed within 2 years of treatment [3, 18, 21, 22]. In our study, all patients included were HR-HPV positive preoperatively and we found that 9.2% of them developed residual/recurrent disease during the two-year postoperative follow-up period, which is consistent with the findings in previous literature. Because of this significant risk, close follow-up of these patients is standard practice. Several risk factors for recurrence of cervical lesions have been suggested in the literature [20, 23]. It is clarified that HPV persistence, viral load, deregulation of HPV gene expression, and host epigenetic mechanisms are the main factors influencing the process of carcinogenesis [24]. And HPV persistence was considered one of the main risk factors for developing HPV-related diseases, including cervical dysplasia and cervical cancer [25]. What’s more, the prognostic signifcance of viral load and HPV persistence were highlighted in women having conization. Bogani et al. investigated the effect of persistent HPV infection on the risk of CIN2 + recurrence in 545 patients undergoing primary conisation [26]. The results showed that the risk of recurrence in patients with persistent HPV infection 6 months after cervical conization was 7.46%, whereas the risk of recurrence of cervical lesions in patients with persistent HPV infection 12 months after cervical conization was 13.1%. In addition, the results of a multicentre, 5-year follow-up study of recurrence rates after loop electrosurgery and laser conisation showed that HPV persistence was the only factor associated with 5-year recurrence [19]. Furthermore, in postmenopausal women, persistent infection with the same HR-HPV genotypes, particularly HPV-18, has been shown to be a risk factor for the development of recurrent CIN2-3 [27]. Therefore, postoperative HPV infection is considered an important risk factor for HSIL recurrence and is now an important test recommended for postoperative follow-up in clinical practice. However, early identification of patients at higher risk of treatment failure may help to avoid delays in retreatment of these patients and reduce unnecessary visits by women at very low risk of developing the disease. A pilot study by Torne et al. was the first to demonstrate that IOP-HPV testing is feasible and accurately predicts treatment failure in patients with CIN2-3. Specifically, treatment failure was found in 12/132 women (9.1%) in the study. The sensitivity, specificity, positive predictive value, and negative predictive value of IOP-HPV testing for treatment failure were superior to other conventional predictors (cone margins, endocervical smears, and 6-month intraoperative cytology), and on multivariate analysis, IOP-HPV was highly associated with treatment failure (OR15.40, 95% CI 1.58–150.42) [28]. J Rabasa et al. performed a similar study to evaluate whether the IOP-HPV test has the same prognostic value as the HPV test performed 6 months after treatment for HSIL to predict treatment failure. They found that the recurrence rate of HSIL was 6%. There was a strong association between a positive IOP-HPV test, a positive 6-month HPV test, a positive HPV 16 genotype, positive surgical margins and HSIL recurrence. The sensitivity, specificity, and positive and negative predictive values of the IOP-HPV test were better than those of the HPV test at 6 months [29]. Therefore, they believe that this new approach may allow early identification of patients with recurrent disease, which will not delay treatment. Genotyping could be useful in identifying high-risk patients. However, the study was only followed up to 12 months post-surgery and to remedy this, the team subsequently published the results of a 24-month follow-up study showing that the recurrence rate of HSIL was 6.2% (19/304). HPV testing after loop electrosurgical resection predicted HSIL recurrence at 24 months with similar diagnostic accuracy to HPV testing at 6 months. The direct economic savings after the provisional suppression of procedures included in the 6-month control assessment per patient with high-grade intraepithelial lesion was estimated to be 172.8 € [30]. These studies prompted us to undertake further investigation, the results of which demonstrated comparable rates of postoperative recurrence and corroborated the assertion that IOP-HPV represents a significant risk factor for postoperative recurrence. However, among patients with IOP-HPV positivity, is there a difference in the risk of postoperative recurrence according to age or menopausal status? To my knowledge, no relevant study has investigated this question. Menopause has been suggested to be associated with persistent HPV infection. Results from a retrospective cohort study by So KA et al. showed that older age (> 50 years) and menopause were associated with persistent HR-HPV infection after cervical conization, and multifactorial analyses showed that menopausal status was the only significant independent predictor of HR-HPV persistence after treatment [31]. However, a study aimed at analysing the characteristics of HPV distribution, prevalence of infection and age risk in premenopausal and postmenopausal women showed that menopause was not associated with HPV infection [32]. In addition, a previous study of HPV infection in 20,000 women from nine provinces in China showed that the prevalence of HR-HPV infection in more than 2,000 postmenopausal women (17.2%) was not significantly different from that in premenopausal women (16.4%) [33]. It is controversial whether menopause increases a patient’s risk of HPV infection. It is also inconclusive whether menopause is associated with recurrence after HSIL treatment. The results of a Korean study showed that menopause (P < 0.001; OR, 3.969), pre- and post-operative HR-HPV load (P < 0.05; OR, 2.430; P < 0.05; OR, 5.351), and infection with multiple HR-HPV types (P < 0.05; OR (2.345) were significantly associated with residual/recurrent CIN after surgery [34]. However, Gosvig CF et al. found that persistent HR-HPV infection after cervical conization was not associated with age [35], and the findings of Amal M.A et al. also demonstrated that age and menopause were not associated with postoperative recurrence of HSIL [36]. This is similar to previously reported studies [37–39]. In our study, the population was all preoperatively HR-HPV positive and pathologically diagnosed with HSIL. We were surprised to find that among them, IOP-HPV positivity at age less than 50 years or premenopausal was more significantly associated with residual/recurrent lesions (including HSIL and LSIL). This observation may be related to more frequent sexual intercourse before age 50 or before menopause. What’s more, postmenopausal women were more likely to have cervical adhesions and strictures after LEEP, making it difficult to diagnose recurrent lesions. This needs to be confirmed and investigated in studies with large samples. By identifying the risk factors for HSIL recurrence and residual disease, the best and most precise way to treat HSIL and IOP-HPV positive patients will be explored. An interesting retrospective multicentrel study in Italy showed that the five-year recurrence rate was 1.7% and 5.7% after conization plus vaccination and conization alone, respectively (p = 0.068) [40]. The recurrence risk of vaccinated patients is slightly lower than that of unvaccinated women, although there is no statistically significant difference. On the basis of our findings, it is perhaps recommended that vaccination after conization may reduce the risk of postoperative recurrence in IOP-HPV-positive patients, this has not yet been studied and is well worth exploring further. This study is one of the few to use intraoperative HPV testing as an early predictor of residual or recurrent cervical HSIL. Our study was performed by the same surgeon to ensure consistency of surgery. There are still some shortcomings of this study. The sample size is small, which may cause some variability in the research results. The follow-up study is expected to address these shortcomings and provide a more in-depth discussion. Conclusion The rate of residual or recurrent lesions after LEEP treatment for HSIL was approximately 9.2%. IOP-HPV positivity was an independent risk factor for residual or recurrent HSIL. In addition, IOP-HPV positivity, age less than 50 years, or premenopausal status were more significantly associated with residual or recurrent lesions. Therefore, IOP-HPV testing for LEEP may have significant clinical value in the early prediction of residual or recurrent high-grade squamous intraepithelial lesions of the cervix, allowing for personalised management and timely follow-up. Larger studies are needed to confirm whether IOP-HPV testing can replace or complement traditional follow-up strategies. Acknowledgements Not applicable. Abbreviations Atypical squamous cells of undetermined signifcance Colposcopically directed biopsy Cervical intraepithelialneoplasia Endocervical curettage High-risk human papillomavirus High-grade squamous intraepithelial lesion Intraoperative post-conisation human papillomavirus Liquid-based cytology ThinPrep cytologic test Loop electrosurgical excisional procedure Low-grade squamous intraepithelial lesion Authors' contributions WX and XL had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of data analysis. Conception and design: WX, XL and XD. Acquisition, analysis, or interpretation of data: WX, SY, CC, and XL. Drafting of the manuscript: WX, YH, and XL. Critical revision of the manuscript for important intellectual content: WX, XD and XL. Statistical analysis: WX, XL,CC. Data Collection: XD, SY, and XL.Supervision: YH. All authors read and approved the final manuscript. Funding Scientific and Technology Project of Wenzhou (grant number Y20210369). Data availability The datasets generated and analysed during the current study are not publicly available due avoid unreasonable use by third parties or organizations, but are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. Informed consent was obtained for all patients or family members. In addition, all methods were performed in accordance with the relevant guidelines and regulations. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets generated and analysed during the current study are not publicly available due avoid unreasonable use by third parties or organizations, but are available from the corresponding author on reasonable request.